New Study Says I Was Wrong About NMN and NR?

Key Takeaways

• Small Norwegian trial: NR raised NAD 2.3× vs NMN.
• 65‑person trial found no NAD difference between NR and NMN.
• Both precursors partly convert to nicotinic acid via gut.
• Human clinical benefits of NR/NMN remain modest and inconsistent.
• Cheaper vitamin B3 may become preferred over premium precursors.

Pulse Analysis

The NAD‑boosting market has been dominated by two rival molecules: nicotinamide riboside (NR), discovered by biochemist Charles Brenner, and nicotinamide mononucleotide (NMN), championed by David Sinclair’s ventures. Both promise to replenish cellular NAD, a co‑factor linked to metabolism and aging, and have spawned multibillion‑dollar supplement lines. Early animal work suggested distinct advantages, fueling a heated commercial rivalry that positioned each compound as the superior anti‑aging ingredient.

New human data are reshaping that narrative. A small crossover study in Norway reported a 2.3‑fold greater NAD increase with NR versus NMN, but the sample size (six participants) limited statistical confidence and showed high intra‑individual variability. In contrast, a more robust 65‑person, double‑blind trial published in Nature Metabolism demonstrated that both NR and NMN roughly doubled circulating NAD after 14 days, with no meaningful difference between them. Mechanistic research now indicates that oral NR and NMN are largely processed by gut microbiota into nicotinic acid (niacin) before entering systemic circulation, blurring the lines between the two precursors and suggesting a shared metabolic pathway.

For the business community, these insights imply that premium pricing based on perceived superiority may be untenable. Investors and regulators should scrutinize claims of unique clinical benefits, especially as larger trials continue to show modest or inconsistent outcomes. Meanwhile, consumers might find comparable NAD elevation from cheaper niacin sources, though tolerability and dosing differ. The industry’s next phase will likely focus on rigorous efficacy studies, transparent labeling, and possibly a shift toward broader B‑vitamin strategies rather than a binary NR‑vs‑NMN marketing battle.